All In Biotech

Drug Trial Radar · NCT06093841

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL: a Single-arm, Multicenter, Open, Phase II Study

Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

46

Planned (sponsor's estimate)

Start

Nov 3, 2023

Primary completion

Jan 21, 2024

Study completion Nov 4, 2029

Sponsor

Sponsor type
Industry
First posted
Oct 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to asess the efficacy of Relmacabtagene autoleucel as second-line therapy in adult patients with aggressive B-cell Non-Hodgkins Lymphoma who are ineligible for haematopoietic stem cell transplantation.

Conditions

  • Lymphoma, Large B-Cell, Diffuse
  • Follicular Lymphoma Grade 3B
  • High-grade B-cell Lymphoma
  • Mediastinal B-Cell Diffuse Large Cell Lymphoma

Interventions

  • Relmacabtagene AutoleucelBiological

    A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

  • FludarabineDrug

    Administered according to package insert

  • CyclophosphamideDrug

    Administered according to package insert

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR at 3 monthTime frame: 3 months

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital

    Beijing, China

  • Peking Union Medical College Hospital

    Beijing, China

  • Jiangsu Provincial People's Hospital

    Nanjing, China

  • Sun Yat-sen University Cancer Hospital

    Guangzhou, Guangdong, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Shandong Cancer Hospital

    Jinan, Shandong, China

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,

    Shanghai, Shanghai Municipality, China

  • Institute of Hematology&Hospital of Blood Disease CAMS

    Tianjin, Tianjin Municipality, China

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, China

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.